Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doris Damian

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Nature Genetics|July 1, 2004
Statistical concerns about the GSEA procedureDoris Damian, Malka Gorfine
Multiple Sclerosis and Related Disorders|April 4, 2021
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An updateDominic Jack, Doris Damian, Axel Nolting, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 10, 2008
Accelerated evolution of resistance in multidrug environmentsMatthew Hegreness, Noam Shoresh, Doris Damian, et al.
The Annals of Otology, Rhinology, and Laryngology|June 22, 2005
Effect of cochlear implantation on residual spiral ganglion cell count as determined by comparison with the contralateral nonimplanted inner ear in humansAayesha M Khan, Ophir Handzel, Doris Damian, et al.
Audiology & Neuro-Otology|May 22, 2013
Smartphone-based hearing test as an aid in the initial evaluation of unilateral sudden sensorineural hearing lossOphir Handzel, Oded Ben-Ari, Doris Damian, et al.
Neurodegenerative Disease Management|August 3, 2022
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summaryPatrick Vermersch, Andrew Galazka, Fernando Dangond, et al.
Current Medical Research and Opinion|December 17, 2020
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: <i>post hoc</i> analysis of subgroups with and without prior disease-modifying drug treatmentPatrick Vermersch, Andrew Galazka, Fernando Dangond, et al.
The Laryngoscope|April 5, 2005
Is word recognition correlated with the number of surviving spiral ganglion cells and electrode insertion depth in human subjects with cochlear implants?Aayesha M Khan, Ophir Handzel, Barbara J Burgess, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Advances in Therapy|November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment MethodsHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Nature Genetics|July 1, 2004
Statistical concerns about the GSEA procedureDoris Damian, Malka Gorfine
Multiple Sclerosis and Related Disorders|April 4, 2021
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An updateDominic Jack, Doris Damian, Axel Nolting, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 10, 2008
Accelerated evolution of resistance in multidrug environmentsMatthew Hegreness, Noam Shoresh, Doris Damian, et al.
The Annals of Otology, Rhinology, and Laryngology|June 22, 2005
Effect of cochlear implantation on residual spiral ganglion cell count as determined by comparison with the contralateral nonimplanted inner ear in humansAayesha M Khan, Ophir Handzel, Doris Damian, et al.
Audiology & Neuro-Otology|May 22, 2013
Smartphone-based hearing test as an aid in the initial evaluation of unilateral sudden sensorineural hearing lossOphir Handzel, Oded Ben-Ari, Doris Damian, et al.
Neurodegenerative Disease Management|August 3, 2022
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summaryPatrick Vermersch, Andrew Galazka, Fernando Dangond, et al.
Current Medical Research and Opinion|December 17, 2020
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: <i>post hoc</i> analysis of subgroups with and without prior disease-modifying drug treatmentPatrick Vermersch, Andrew Galazka, Fernando Dangond, et al.
The Laryngoscope|April 5, 2005
Is word recognition correlated with the number of surviving spiral ganglion cells and electrode insertion depth in human subjects with cochlear implants?Aayesha M Khan, Ophir Handzel, Barbara J Burgess, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Advances in Therapy|November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment MethodsHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Pageof 2